

RESOURCES

PEOPLE

Amgen (Thousand Oaks, CA) has appointed **Fabrizio Bonanni** senior vice president, quality and compliance. Mr. Bonanni most recently held the position of corporate vice president, regulatory/clinical affairs at Baxter International. He succeeds **Daryl Hill**, who retired in March after 15 years with Amgen.

Genelabs Technologies (Redwood City, CA) has announced the retirement of **Irene Chow** as president and CEO. Dr. Chow has been appointed chairman of the board of directors, and will be succeeded as president by **James A.D. Smith**, who was promoted from COO, a position he has held since October 1996.

ChiRex (Stamford, CT) has announced the appointment of **Thomas I.H. Dubin** as vice president, general counsel and secretary. Previously, Mr. Dubin was assistant general counsel, corporate affairs of Warner-Lambert, and was formerly with Cravath, Swaine & Moore in New York.

Diana D. Lees has been named director, new business ventures at CombiChem (San Diego, CA). Previously, she was market development manager at Argonaut Technologies. CombiChem has also announced the departure of **Karin Eastham**, CFO and vice president, finance and administration, to pursue another opportunity.

Procept (Cambridge, MA) has named **Michael Fitzgerald** chief financial officer and vice president of finance. He joins Procept from CytoMed, where he served as vice president and CFO.

David Foster has been named director of government relations at Biogen (Cambridge, MA). He joins Biogen from Genzyme, where he served in the same capacity, and before that served as deputy general counsel for the US Department of Health and Human Services.

EntreMed (Rockville, MD) has named **Joanna C. Horobin** senior vice president of commercial development, a newly created post. Dr. Horobin comes to EntreMed from Rhône-Poulenc Rorer, where she served as vice president of corporate marketing, oncology.

Embrex (Research Triangle Park, NC) has appointed **Brian Hrudka** vice president, global commercial development. Most recently, he led the GMP manufacturing, logistics, and customer service divisions at Novartis Animal Health.

Edward L. Jacobs has joined SuperGen (San Ramon, CA) as executive vice president, commercial operations. Before joining the company, he was employed at Sequus Pharmaceuticals as senior vice president, commercial operations.

Advanced Cell Technology (Worcester, MA) has named **Robert Lanza** senior director of tissue engineering and transplant medicine. Dr. Lanza joins ACT from BioHybrid Technologies, where he has spent the past nine years, most recently as director of transplantation biology.

David J. Main, vice president of corporate development for Inex Pharmaceuticals (Vancouver, BC, Canada), has been named to replace **James J. Miller** as president and CEO, effective in July. Dr. Miller will continue on in his position as chairman of the board.

Kevin Mullane has been appointed to the post of executive vice president, research at Axiom Biotechnologies (San Diego, CA). He joins Axiom from Chugai Biopharmaceuticals,

where he was senior vice president, research and development.

Cytel (San Diego, CA) has announced the appointment of **Lisabeth F. Murphy** to its board of directors. Ms. Murphy is currently executive vice president, intellectual property and legal affairs at Elan.

Pharmacopeia (Princeton, NJ) has promoted **Bruce Myers** to senior vice president and chief financial officer, replacing **Lewis J. Shuster**, who becomes president and COO of the company's laboratory operations. Mr. Myers joined Pharmacopeia last year as CFO of its subsidiary, Molecular Simulations.

RiboGene (Hayward, CA) has announced the appointment of **Anastassios D. Retzios** as director of clinical operations. Dr. Retzios was previously at Alpha Therapeutic, where he served most recently as associate director of clinical research.

David M. Rosen has been named vice president of operations, a newly created position, at Hyseq (Sunnyvale, CA). He joins the company from Celtrix Pharmaceuticals, where he was most recently senior vice president, R&D. Hyseq also announced two promotions: **Mark Gitter** to CFO, and **Nandini Tandon** to vice president, corporate development and corporate communications.

John J. Serbin, formerly vice president of marketing and corporate development at Point Biomedical, has been appointed to the newly created position of vice president, corporate development at Idun Pharmaceuticals (La Jolla, CA).

Joel Claiborne Stephens has been named director of population genomics at Genaissance Pharmaceuticals (New Haven, CT). Before his appointment, Dr. Stephens headed the bioinformatics group at the National Cancer Institute's laboratory of genomic diversity.

Boston Scientific Corp. (Natick, MA) has named **James R. Tobin** as president and chief executive officer. Mr. Tobin, who will also serve on the company's board, recently resigned from his positions as president and CEO of Biogen.

British Biotech (Oxford, UK) has announced the appointment of **Tony Weir** as finance director, succeeding **Malcolm Fallen**, who resigned from the board of directors in March. Mr. Weir joined the company in 1990, and has been finance director of its principal operating subsidiary, British Biotech Pharmaceuticals, since 1997.



Visit the nature family on
the world wide web at:
<http://www.nature.com>

or access each sister journal
directly:

nature
biotechnology

<http://www.biotech.nature.com>

nature
genetics

<http://www.genetics.nature.com>

nature
medicine

<http://www.medicine.nature.com>

nature
structural
biology

<http://www.structbio.nature.com>